Chemours Company (The) (CC)

Chemours Company (The)'s Q·Score is 5.3/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Forward P/E of 10.1× is low relative to sector peers. Key area to monitor: currently unprofitable (-7% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for CC is $26.33, based on ratings from 9 Wall Street analysts. This is 15.2% above the current price of $22.85. Price targets are forward-looking estimates and not guarantees of future performance.

Chemours Company (The) (CC) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 10.1×. The consensus analyst price target of $26.33 is 15% above the current price.

Chemours Company (The)'s next earnings report is expected on approximately August 4, 2026.

Chemours Company (The) has a net profit margin of -7.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 15.2%, reflecting a more cost-intensive business model.

Chemours Company (The) is reporting modest revenue growth of 1.0%.

Chemours Company (The) has a debt-to-equity ratio of 20.34×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 1.82×, indicating comfortable short-term liquidity.